IN-DEPTH ANALYSIS
Market Sell-Off Triggered by Moderated Full-Year Growth Outlook
Shares of Sandoz plummeted by up to 8% in Zurich trading after executive leadership moderated the company’s full-year net sales trajectory during its third-quarter financial presentation. The generic drugmaker now projects constant-currency net sales growth between 5% and 6%, dialing back earlier expectations of mid-to-high single-digit expansion.
In contrast to moderated top-line revenue forecasts, underlying financial resilience emerged as a key institutional positive. Sandoz revised upward its core EBITDA margin outlook to between 23% and 23.5% for 2026, advancing well beyond the prior baseline of a 100-basis-point increase over the 21.7% recorded in 2025 and affirming disciplined cost stewardship.
Full-year constant-currency revenue guidance was recalibrated to a focused range of 5% to 6%.
Core EBITDA margin expectations were upgraded to 23%-23.5%, reflecting structural operational efficiencies.
"Short-term supply bottlenecks in biosimilars temporarily hindered third-quarter top-line execution, yet core underlying operational earnings continue to display remarkable durability." — Richard Saynor, Chief Executive Officer of Sandoz
















